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Abstract Atopic dermatitis (AD) is an inflammatory,
chronically relapsing, pruritic skin disease and lesions
associated with AD are frequently colonized with Staphy-
lococcus aureus (S. aureus). Activation of T cells by
staphylococcal enterotoxins (SE) plays a crucial role in the
pathogenesis of AD. Previous studies have demonstrated
that lidocaine could attenuate allergen-induced T cell
proliferation and cytokine production in peripheral blood
mononuclear cells (PBMCs) from asthma patients. The
purpose of this study was to investigate the effects of
lidocaine on SE-stimulated activation of PBMCs from AD
patients. PBMCs were isolated from ten AD patients and
stimulated by staphylococcal enterotoxin A (SEA) or
staphylococcal enterotoxin B (SEB) in the presence or
absence of lidocaine in various concentrations. Cellular
proliferation and the release of representative TH1- and
TH2-type cytokines were measured. The effect of lidocaine
on filaggrin (FLG) expression in HaCaT cells co-cultured
with SE-activated PBMCs was also examined. Our results
demonstrated that lidocaine dose-dependently inhibited the
proliferative response and the release of IL-4, IL-5, IL-13,
TNF-a, and IFN-c from SEA- and SEB-stimulated PBMCs
and also blocked the down-regulation of FLG expression in
HaCaT cells co-cultured with SEA- and SEB-activated
PBMCs. These results indicate that lidocaine inhibited
SEA- and SEB-stimulated activation of PBMCs from
patients with AD. Our findings encourage the use of lido-
caine in the treatment of AD.
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Introduction
Skin lesions associated with atopic dermatitis (AD) are
frequently colonized by Staphylococcus aureus (S. aureus)
[23], which secrete two kinds of major staphylococcal
enterotoxins A (SE), staphylococcal enterotoxin (SEA) and
staphylococcal enterotoxin B (SEB), that are characteristic
of staphylococcal superantigens (SsAgs) and bind to major
histocompatibility complex class II molecules and selec-
tively activate T cells expressing certain T cell receptor
(TCR) Vb-chain families. Therefore, SEA and SEB can
precipitate or aggravate cutaneous inflammation in AD by
induction of T cell proliferation and cytokine secretion [32,
43]. Reportedly, SEB-stimulated peripheral blood mono-
nuclear cells (PBMCs) from AD patients and increased
TH2 cytokine production were compared with healthy
controls [19]. The TH2 cytokine milieu in AD is now
thought to play a significant role in the destruction of skin
barrier function [13]. In addition to superantigen activity,
SsAgs also have been shown to induce inflammation and
exacerbate disease activity by production of superantigen-
specific IgE in patients with AD [37]. There have been
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various reports correlating disease activity in AD with
superantigen production and with specific levels of anti-
superantigen IgE [24, 26, 27]. Furthermore, SsAgs can
inhibit the suppressive ability of regulatory T cells [3].
Thus, SsAg-induced T cell proliferation and subsequent
cytokine production can be considered as a target in the
management of AD.
AD is a chronic and relapsing T cell-mediated inflam-
matory skin disorder [8], which is likely driven by epi-
dermal barrier dysfunction of the damaged skin and
impaired host immune responses [42]. Filaggrin (FLG) is
essential for the epidermal barrier formation and integrity
and FLG gene mutations are the most recognized causes of
skin barrier dysfunction and are considered as predisposing
factors to AD [6]. Reportedly, tumor necrosis factor alpha
(TNF-a), interleukin (IL)-4, and IL-13 are overexpressed in
AD lesions and significantly down-regulate calcium-
induced FLG expression in epidermal keratinocytes (KCs),
which may contribute to skin barrier abnormalities [1, 13,
18]. Thus, skin barrier repair by blocking production of
inflammatory cytokines that down-regulate FLG expres-
sion suggests a probable treatment strategy for AD.
Lidocaine is often clinically used as a short-acting local
anesthetic and antiarrhythmic agent [40], as it possesses
anti-inflammatory effects, and can be used as an immu-
nomodulatory drug in treatment against allergic diseases
[12, 29], as nebulized lidocaine was shown to be an
effective and safe therapy in patients with mild-to-moder-
ate asthma [14, 20, 39]. Recent studies have also demon-
strated that lidocaine and its analogue JMF2-1 inhibited the
activation of T lymphocytes and generation of important
cytokines [17, 21, 30].
In the present study, we examined the effects of lido-
caine on SEA- and SEB-stimulated cell proliferation and
cytokine production in PBMCs from AD patients. Fur-
thermore, the effect of lidocaine on FLG expression in
HaCaT cells, a well-known immortalized human kerati-




The following reagents were used: hydrochloride lidocaine
(Sigma-Aldrich, St. Louis, MO, USA); SEA and SEB
(Toxin Technology, Inc., Sarasota, FL, USA); cell lysis
buffer for western blotting and immunoprecipitation (IP)
analysis, phenylmethanesulfonyl fluoride (PMSF) and
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) sample loading buffer (59) (Beyotime
Institute of Biotechnology, Beijing, China); Dulbecco’s
modified Eagle’s medium (DMEM)-high glucose, fetal calf
serum (FCS), serum-free keratinocyte medium for culture
of human KCs and Dispase II (GIBCO-BRL, Gland Island,
NY, USA). If not otherwise stated, the reagents were
obtained from Sigma-Aldrich Chemie GmbH (Deisenho-
fen, Germany).
Subjects
Patient consent and ethical approval were obtained prior
to the study. A total of ten AD patients (four males and
six females; mean age, 27.75 years), who were admitted
to our hospital, were included in the present study
(Table 1). AD was diagnosed in accordance with the
criteria of Hanifin and Rajka. The severity of disease was
evaluated using the SCORing Atopic Dermatitis (SCO-
RAD) index [34], which categorizes cases as mild (0–24
points), moderate (25–50 points) and severe (51–103
points). Venous blood samples were collected from AD
patients and analyzed for total serum IgE level using a
Pharmacia UniCAP-100 automatic immunoassay analyzer
(Pharmacia Diagnostics AB, Uppsala, Sweden). None of
the AD patients were currently administered with sys-
temic steroids or immunosuppressant treatments, or uti-
lizing potent topical steroids. This study was approved by
the Ethics Committee of Shanghai Jiaotong University
School of Medicine (Shanghai, China).
Table 1 Clinical data for the
ten AD cases in the present
study
Patient no. Sex Ethnicity Age at onset (years) SCORAD Total serum IgE (IU/mL)
1 F Han Chinese 29 15.1 110
2 M Han Chinese 12 56.5 27,700
3 F Han Chinese 67 27.5 830
4 F Han Chinese 32 53 9,930
5 F Han Chinese 10 38.5 2,160
6 M Han Chinese 35 12.6 150
7 M Han Chinese 9 49 8,710
8 F Han Chinese 48 30.5 670
9 F Han Chinese 25 54 16,100
10 M Han Chinese 10 40.5 6,108
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PBMC purification
PBMCs were isolated from heparinized venous blood from
AD patients on Ficoll-Hypaque gradients (Pharmacia,
Uppsala, Sweden) and resuspended in Roswell Park
Memorial Institute (RPMI) 1,640 medium supplemented
with gentamicin (40 lg/mL) and 10 % pooled type AB
normal human serum (Sigma-Aldrich). In all experiments,
cells were cultured under the atmosphere containing 5 %
CO2 at 37 C.
Analysis of lidocaine cytotoxicity on PBMCs
PBMCs (1 9 105 cells/well) were cultured for up to 7 days
in the presence or absence of lidocaine. Cell viability was
determined using the Cell Counting Kit-8 (CCK-8) assay
kit (Beyotime Institute of Biotechnology) according to the
manufacturer’s instructions.
Cellular proliferation and cytokine production analysis
Freshly isolated PBMCs (1 9 105 cells/well) were cultured
with SEA (100 ng/mL) and SEB (100 ng/mL) in the
presence of different concentrations of lidocaine in 96-well
plates for 7 days. Cells were pulsed with 1 l Ci of tritiated
methyl thymidine (Radiochemical Center, Amersham, UK)
for the last 8 h of the culture period. The stimulation index
was calculated by dividing the counts per million allergen-
stimulated cultures by that of unstimulated cultures. For
cytokine production analysis, PBMCs (1 9 106 cells) were
cultured with or without SEA (100 ng/mL) or SEB
(100 ng/mL) for 72 h in the presence of different lidocaine
concentrations. The levels of IL-4, IL-5, IL-13, IL-10, IL-
12, IL-2, interferon gamma (IFN-c), and TNF-a in the
supernatant were measured with enzyme-linked immuno-
sorbent assay (ELISA) kits (BioSource International, Inc.,
Camarillo, CA, USA).
Co-culture experiment
HaCaT cells were grown in DMEM supplemented with
10 % FCS, 1 % penicillin–streptomycin, and differentiated
in high CaCl2 (10 mM) to up-regulate FLG expression for
48 h at 37 C and 5 % CO2, as previously described [13].
A co-culture system was established by culturing HaCaT
cells and PBMCs using a polycarbonated trans-well insert
membrane containing 0.4 lm pores (Becton-Dickinson &
Company, Franklin Lakes, NJ, USA). Briefly, HaCaT cells
(1 9 105 cells/mL) were cultured at the bottom of 12-well
plates, whereas PBMCs (2 9 106 cells/mL) were cultured
on the polycarbonated insert membranes. In the co-culture
system, cells were cultured for 48 h in RPMI 1,640 med-
ium supplemented with gentamicin (40 lg/mL) and 10 %
pooled type AB normal human serum. The cells were then
washed with phosphate-buffered saline and further incu-
bated with serum-free medium for 24 h before stimulation.
SEA and SEB were then added to the PBMCs alone or with
lidocaine and cultured for an additional 72 h. As a control,
HaCaT cells were cultured in 12-well plates with mem-
brane inserts, but without PBMCs.
RNA isolation and analysis
Total RNA was extracted from cells after treatment
according to the experimental requirement. RNA extraction
was performed using RNeasy Mini Kits (Qiagen, Valencia,
CA, USA) according to the manufacturer’s guidelines.
Total RNA (1 lg) was reverse-transcribed using the iScript
cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA) at
25 C for 5 min and 42 C for 30 min, followed by 85 C
for 5 min in a final reaction volume of 40 lL. All assays
were carried out under the following conditions: 35 cycles
of denaturation at 95 C for 15 s, followed by annealing
and extension at 60 C for 60 s using the ABI7300 Real
Time PCR System (Applied Biosystems, Inc., Foster City,
CA, USA). Melt curve analysis was performed to confirm
the specificity of the amplified products. All samples were
run in triplicate and relative expression was determined by
normalizing samples to b-actin. Data were analyzed using
the comparative DDCt method. Primers and probes for
human FLG and b-actin were purchased from Applied
Biosystems.
Western Blot analysis
For Western Blot analysis, protein extracts (30 lg) were
prepared by lysing the cells in lysis buffer containing
protease and phosphatase inhibitors, separated by SDS-
PAGE, and transferred to polyvinylidene difluoride mem-
branes. Membranes were blocked for 2 h in TBS [50 mM
Tris–HCl (pH 7.5) and 150 mM NaCl] containing 0.1 %
Tween 20 and 5 % non-fat dried milk. Mouse anti-human
b-actin antibody (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) and mouse anti-human FLG antibody (Vector
Laboratories, Inc., Burlingame, CA, USA) were used for
western blotting. Subsequently, the membranes were
incubated for 1 h with goat anti-mouse immunoglobulin
(IgG) conjugated to horseradish peroxidase, rewashed, and
developed using ECLTM reagents (Amersham Pharmacia
Biotech, Inc., Piscataway, NJ, USA) and exposed to film.
Statistical analysis
Results are presented as mean ± SEM. Significant differ-
ences between groups were examined using the Wilcoxon
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We initially investigated the cytotoxic effect of lidocaine
on PBMCs from AD patients by culturing PBMCs in the
presence or absence of different lidocaine concentrations
for 7 days. Cell viability post-incubation was detected
using the CCK-8 assay. We found that lidocaine at con-
centration up to 100 lmol/L did not affect PBMC viability,
whereas concentrations at 1,000 lmol/L significantly
decreased the percentage of viable cells (Fig. 1). Thus,
subsequent experiments were performed with lidocaine
concentrations B100 lmol/L.
Lidocaine inhibited SEA- and SEB-induced T cell
proliferation
PBMCs from ten AD patients were stimulated by SEA,
SEB, or phorbol myristate acetate (PMA) plus calcium
ionophores in the presence or absence of lidocaine. Cellular
proliferation was assessed by tritiated thymidine incorpo-
ration and expressed as stimulation index (SI). Our results
demonstrated that lidocaine at 100 lmol/L significantly
inhibited the proliferative response of PBMCs stimulated
by SEA or SEB (p \ 0.05, Fig. 2). We also found that
lidocaine at 100 lmol/L inhibited PMA/calcium iono-
phore-stimulated proliferative responses, which was in
agreement with a previous report [39].
Lidocaine suppressed cytokine production
in SEA- and SEB-stimulated PBMCs
Next, we tested the ability of lidocaine to reduce cytokine
production in PBMCs from AD patients stimulated by SEA
or SEB. Stimulation with SEA or SEB increased release of
IL-4, IL-5, IL-13, TNF-a, IFN-c, IL-2, IL-10, and IL-12 in
PBMCs from AD patients, whereas lidocaine (100 lmol/L)
significantly reduced IL-4, IL-5, IL-13, TNF-a, and IFN-c
production following SEA or SEB stimulation (p \ 0.05,
Figs. 3, 4). However, no similar inhibitory effects of
lidocaine on IL-2, IL-10, and IL-12 production were
observed (Figs. 3, 4).
Lidocaine blocked the down-regulation
of FLG expression in HaCaT cells co-cultured
with SEA- and SEB-activated PBMCs
Next, we further investigated the effect of lidocaine on
FLG expression in HaCaT cells co-cultured with SEA- and
SEB-activated PBMCs and found that FLG mRNA levels
in HaCaT cells co-cultured with activated PBMCs were
Fig. 1 Changes in PBMC viability after incubation with lidocaine.
PBMCs from ten AD patients were cultured for up to 7 days in the
presence or absence of lidocaine. The percentage of viable cells
decreased significantly following exposure to 1,000 lmol/L of
lidocaine (*p \ 0.05, **p \ 0.01, and ***p \ 0.001 vs. untreated
control)
Fig. 2 Proliferative responses of PBMCs from ten AD patients after
stimulation with SEA, SEB, or PMA plus calcium ionophore in the
presence or absence of lidocaine. The stimulation index (SI) was
calculated. Proliferative responses were significantly decreased with
100 lmol/L of lidocaine. (Comparisons were between the two treated
groups and un-treated control; *p \ 0.05 and **p \ 0.01, respectively)
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significantly lower than those in HaCaT cells cultured
alone. In the co-culture system, the addition of lidocaine
(100 lmol/L) to PBMCs blocked the down-regulation of
FLG expression, both at the mRNA (Fig. 5a) and protein
levels (Fig. 5b, c), following induction by SEA- and SEB-
activated PBMCs.
Fig. 3 IL-4, IL-5, IL-13, TNF-a, IFN-c, IL-2, IL-10, and IL-12
production by PBMCs from ten AD patients after SEA stimulation in
the presence or absence of lidocaine measured via ELISA. Lidocaine
(100 lmol/L) significantly decreased SEA-induced IL-4, IL-5, IL-13,
TNF-a, and IFN-c production in PBMCs from AD patients.
(Comparisons were between the two treated groups and nontreated
control, respectively, *p \ 0.05, **p \ 0.01, and ***p \ 0.001 vs.
untreated control)
Fig. 4 IL-4, IL-5, IL-13, TNF-a, IFN-c, IL-2, IL-10, and IL-12
production by PBMCs from ten AD patients after stimulation with
SEB in the presence or absence of lidocaine measured via ELISA.
Lidocaine (100 lmol/L) significantly decreased SEB-induced IL-4,
IL-5, IL-13, TNF-a, and IFN-c production in PBMCs from AD
patients. (Comparisons were between the two treated groups and
nontreated control, respectively, *p \ 0.05, **p \ 0.01, and
***p \ 0.001)
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Discussion
To the best of our knowledge, the present study is the first
to demonstrate lidocaine inhibition of PBMC proliferation
in response to SEA and SEB stimulation. In addition, the
production of both TH1-type cytokines (TNF-a and IFN-c)
and TH2-type cytokines (IL-4, IL-5, and IL-13) from SEA
and SEB-activated PBMCs was inhibited by lidocaine at a
concentration of 100 lmol/L. These new findings indicate
that lidocaine may exert immunoregulatory effects on
immune cells and can be used as an anti-inflammatory
agent in the treatment of AD.
The skin lesions present in AD are frequently colonized
with S. aureus strains that produce SsAgs [23, 43] and
recent evidence has indicated that one type of skin-homing
T cell (CD4 ?/Foxp3 ?) in AD patients exerts effector
TH2-like functions promoting SsAg stimulation, which
may aggravate allergic skin inflammation [25]. SsAgs also
have the ability to augment antigen-specific TH1 responses
by stimulating antigen-presenting cells, which might con-
tribute to AD chronification [2], and can contribute to AD
pathogenesis by increasing the frequency of memory T
cells that are able to migrate to and be activated within AD
lesions, where they directly contact epidermal KCs [38].
Several cytokines, including TNF-a, IL-4, and IL-13, are
released from T cells and monocytes and were found to
down-regulate FLG expression in KCs [13, 18], thus con-
tributing to compromised skin barrier function.
Staphylococcus aureus can colonize AD skin and simul-
taneously secrete SEA and SEB, which can subsequently
induce the release of TNF-a, IL-4, and IL-13 from immune
cells that, in turn, can down-regulate FLG expression in KCs.
Thus, we evaluated the inhibitory effect of lidocaine on
activated PBMCs via measuring FLG expression in HaCaTs
and PBMCs in a co-culture system in which PBMCs were
stimulated with SEA and SEB together to mimic an in vivo
environment. Our results showed that lidocaine significantly
blocked FLG down-regulation in HaCaT cells co-cultured
with SEA and SEB-stimulated PBMCs. We ascribe this
effect of lidocaine to its inhibition of cytokine production
(i.e., TNF-a, IL-4, and IL-13) in activated PBMCs, sug-
gesting that lidocaine may exert an inhibitory effect on
inflammatory T cells activated by SE, which, in turn, provide
beneficial effects to skin barrier repair.
Glucocorticosteroids are commonly used drugs for AD
treatment, although corticosteroid treatment has been
challenged for its adverse effects on the skin barrier.
Topical corticosteroid application can delay epidermal
barrier restoration, lead to epidermal thinning, and even
induce a strong reduction in human beta-defensin produc-
tion [16, 31, 36]. In this context, lidocaine, with its
inhibitory effect on PBMCs and potential to improve skin
barrier function, may be used as a novel treatment against
AD. Nevertheless, the use of lidocaine–prilocaine cream (a
eutectic mixture of local anesthetics) in pediatric and der-
matologic practice to obtain local anesthesia, can also
cause many skin side effects, which include transient skin
blanching, erythema, urticaria, allergic contact dermatitis,
irritant, contact dermatitis, hyperpigmentation, and purpura
[4, 7, 10, 28, 33]. Thus, further studies on animals or
patients are still needed and the safety of lidocaine for the
treatment of AD should be evaluated as well.
Previous studies have demonstrated that lidocaine can
relax smooth airway muscles by decreasing intracellular
Ca2? concentrations [15]. Activation of Ca2?, K?, and Cl-
channels is important for activation of T-cells in the early
phase of an immune reaction [35, 41]. Elevation of Ca2?
plays a critical role in the activation and translocation of
nuclear transcription factors, including nuclear factor (NF)
AT, NF-jB, and c-Jun N-terminal kinase (also known as
mitogen-activated protein kinase 8) [5, 11]. Moreover,
recent studies have reported that lidocaine attenuates
lipopolysaccharide-induced acute lung injury and inhibits
epithelial chemokine secretion through inhibition of NF-
jB activation [9, 22], thus, inhibition of cytokine produc-
tion and T cell proliferation by lidocaine is likely related to
Fig. 5 The effects of lidocaine on FLG expression in HaCaT cells
were studied in a trans-well co-culture system. PBMCs from ten AD
patients were seeded on the surface of insert membrane and HaCaT
cells were seeded on the bottom of the plate. FLG expression was
analyzed using real-time RT-PCR and western blotting. Lidocaine
significantly inhibited FLG down-regulation in HaCaT cells co-
cultured with PBMCs in the presence of SEA and SEB at both the
mRNA (a) and proteins (b) levels. c Densitometric analysis of the
western blotting results is shown, in which the intensity of the protein
signal normalized against the b-actin signal. (Comparisons were
between the two treated groups and nontreated control, respectively,
*p \ 0.05 and **p \ 0.01)
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its down-regulation of NF-jB signaling [21]. Therefore,
the inhibitory effects of lidocaine on SEA- and SEB-
induced PBMC proliferation and cytokine production may
occur through the inhibition of the NF-jB pathway; how-
ever, the precise underlying molecular mecha-
nism(s) require further exploration.
In conclusion, herein, we demonstrated the inhibitory
effects of lidocaine against SEA- and SEB-stimulated
activation of PBMCs from AD patients. Therefore, lido-
caine is a promising anti-inflammatory agent in the treat-
ment of AD.
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